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Controlled delivery of vascular endothelial
growth factor promotes neovascularization
and maintains limb function in a rabbit
model of ischemia
Steven P. Hopkins, MD, Jeffrey P. Bulgrin, BS, Rick L. Sims, BS, Brad Bow-
man, BS, Duane L. Donovan, MD, and Steven P. Schmidt, PhD, Akron, Ohio
Purpose: Vascular endothelial growth factor (VEGF) modulates new blood vessel develop-
ment and growth and has been suggested as a potential therapeutic agent that could allevi-
ate debilitating claudication in patients. The objective of this study was to determine
whether controlled, local delivery of a low dose of VEGF from an osmotic pump could pro-
mote neovascularization, limb perfusion, and functional improvements in the hind limbs of
rabbits rendered partially ischemic by surgery. The effects of VEGF were compared with
those of the vasodilator nitroglycerin (NTG) and to saline administered similarly.
Methods: Thirty rabbits were randomly assigned to either VEGF (n = 10), NTG (n = 10),
or saline (n = 10) treatment groups. Partial ischemia was induced in each left hind limb
by surgical ligation of the common and superficial femoral arteries, leaving the internal
iliac artery intact. The right limb of each animal served as a nonischemic control. Imme-
diately after vessel ligations, a 28-day osmotic pump was implanted to deliver VEGF
(0.22 µg/kg/day), NTG (17.8 µg/kg/day), or saline solution into the common iliac
artery just proximal to the ligation site. Comparative vascularity between ischemic and
nonischemic limbs within treatment groups and between groups was evaluated by (1)
capillary counts from representative fields of hematoxylin and eosin stained muscle tis-
sue taken from hind limbs at day 40; (2) digitized arteriograms of ischemic legs at day
40, which were used to quantify the complexity of vascular branching (fractal dimension
index) and the total extent of vascularization (vascular density index); (3) measuring
capillary refill times in ischemic limbs; and (4) observations of functional and trophic
changes in ischemic limbs. Statistical differences between treatment groups were evalu-
ated by one-way ANOVA.
Results: Complexity of vascular branching and vascular density were significantly greater
(p < 0.001) in VEGF-treated ischemic limbs compared with NTG- and saline-treated
ischemic limbs. By postoperation day 14, all VEGF-treated ischemic limbs had restored
capillary refill (p < 0.001), new hair growth, and greatly improved limb function and
appearance. Saline-treated limbs exhibited ischemic changes, with poor capillary refill
and negligible limb function. Capillary refill in NTG-treated ischemic limbs did not dif-
fer significantly from saline-treated limbs. Ischemic VEGF-treated limbs had signifi-
cantly more capillaries compared with both ischemic and nonischemic limbs in saline-
treated animals (p < 0.05). Ischemic NTG-treated limbs also had significantly more cap-
illaries compared with ischemic limbs in saline-treated animals (p < 0.05). Because of
high variability, however, capillary counts in VEGF-treated ischemic limbs did not dif-
fer significantly from those of contralateral nonischemic limbs, or from capillary counts
in either ischemic or nonischemic limbs of NTG-treated rabbits. 
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Effective treatment of peripheral arterial occlu-
sive disease requires enhancement of limb function
by increasing perfusion and reducing tissue hypoxia.
Current conventional therapies to treat chronic
ischemia have considerable limitations. Surgical
revascularization is not recommended for an increas-
ing number of elderly patients who are poor surgical
risks. Newly developed endovascular interventions
such as rotational atherectomy, laser-assisted angio-
plasty, and stenting may prove useful, but currently
result in a significant percentage of restenosis failures
in peripheral vascular patients.1-3 Exercise therapy
may also be impractical for immobile patients such as
amputees, or difficult for patients with substantial
pain from ischemia.
The concept of therapeutic angiogenesis in the
treatment of peripheral vascular disease has evolved
from the recent discovery of several polypeptide
growth factors responsible for normal as well as
pathologic blood vessel growth.4,5 This novel
approach may help to alleviate morbidity associated
with chronic ischemia. One growth factor that
shows particular promise is vascular endothelial
growth factor (VEGF).6-8
VEGF is an endothelial specific mitogen. It exists
as one of four known homodimeric isoforms.9 The
165 amino acid isoform (VEGF165) is secreted by a
variety of normal and transformed cells; in vitro
studies have shown it to induce mitogenic activity in
endothelial cells but not in epithelial, mesenchymal,
or neuroectodermal cells.7 Increased VEGF expres-
sion has also been shown in a variety of tumor cell
lines.7-9
Recent experiments have used exogenous VEGF
to reverse perfusion deficits in both myocardial and
peripheral vascular ischemic animal models.10-16 Sin-
gle bolus intraarterial delivery or intramuscular
injections of VEGF at doses from 0.5 to 3 mg have
induced significant increases in muscle capillary den-
sity in treated limbs with corresponding functional
and physiologic improvements.12-16 However, clini-
cal use of such large dosages may be expensive and
could also lead to adverse systemic effects due to
unwanted angiogenesis, such as tumor metastasis
and pathologic retinopathy.5, 9 Therefore we hypo-
thesized that much lower doses of VEGF, delivered
locally in a controlled fashion, may be sufficient to
produce a beneficial result. This rationale was also
based on the fact that minute concentrations of
other growth factors are sufficient to initiate a cas-
cade of complex physiologic responses in organ-
isms.17
The efficacy of therapeutic angiogenesis in the
treatment of peripheral vascular disease may not be
due entirely to new vessel formation and growth.
Vasodilation of existing stenosed or collateral ves-
sels may also prove effective in restoring blood flow
to ischemic tissues. In fact, VEGF also induces
endothelium-dependent vasodilatory responses.18-20
Thus, the vasodilator nitroglycerin (NTG) was
chosen as a control in an attempt to test the effec-
tiveness of vasodilatory responses alone without
introducing the confounding effects of exogenous
angiogenic agents.
We evaluated comparative tissue perfusion, vas-
cularity, and limb function in a rabbit model of par-
tial hind limb ischemia with a low dose of VEGF
delivered continuously through an osmotic pump
over a 28-day period. Results were compared with
control groups of ischemic limbs that were perfused
with either NTG or saline alone over the same peri-
od. The nontreated contralateral leg of each rabbit
served as a nonischemic control.
METHODS AND MATERIALS
Preparation of the osmotic pump and treat-
ments. Controlled intraarterial delivery of either
VEGF, NTG, or saline was achieved with a 28-day
Alzet 2ML4 osmotic pump (Alza Corp., Palo Alto,
Calif.). Care was taken to follow the manufacturer’s
filling instructions precisely. A delivery catheter for
each osmotic pump was made by cutting a 6 cm
length of 0.030 inch internal diameter Tygon tub-
ing (Norton Inc., Akron, Ohio) and securing one
end to the inlet port of the pump. The catheter
delivery tip was made from a short segment (approx-
imately 1.5 cm) of 22 gauge intravenous catheter
(Becton and Dickenson, Sandy, Utah) and inserted
into the Tygon tubing until 9 mm remained
exposed. The 9 mm length was chosen based on
Conclusions: Controlled release of microgram quantities of VEGF significantly enhanced
neovascularization and vascular perfusion in ischemic limbs compared with controls in
this rabbit model of partial ischemia. In addition, VEGF-treated ischemic limbs demon-
strated near-normal function and appearance, whereas NTG- and saline-treated ischemic
controls remained noticeably impaired. This novel approach of VEGF delivery may
prove clinically useful either alone or combined with revascularization procedures. 
(J Vasc Surg 1998;27:886-95.)
prior autopsy evaluations that determined the aver-
age distance from the inguinal ligament to the
branching of the internal iliac artery from the com-
mon iliac artery to be approximately 8 mm. This
ensured accurate positioning of the catheter tip into
the nutrient internal iliac artery. Each delivery
catheter was sterilized with ethylene oxide before
filling.
Recombinant human VEGF165 was a generous
gift from Genentech Corporation (South San 
Francisco, Calif.). Aliquots of purified VEGF (25
µg) were brought to room temperature and added
to 2 ml of normal saline containing 100 units of
heparin. This solution was then injected into the
reservoirs of 10 osmotic pumps. NTG (Tridil) was
obtained from the pharmacy of Summa Health 
System in an injectable form (5 mg/ml). In a simi-
lar fashion, 10 aliquots of NTG were used to give 2
mg NTG in 2 ml of normal saline containing 100
units of heparin; this solution was injected into 10
pumps. Ten pumps received 2 ml of heparinized
saline alone. After each pump was loaded with the
appropriate treatment, the delivery catheter was
attached. Twelve hours before implantation, the
entire pump assembly was activated by placing it in
a sterile container of physiologic saline (Baxter
Healthcare Corp, Deerfield, Ill.) at 38° C.
Animal model and surgical procedure. All
experimental protocols and animal care complied
with the Guide for the Care and Use of Laboratory
Animals, Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research
Council (Washington: National Academy Press,
JOURNAL OF VASCULAR SURGERY
888 Hopkins et al. May 1998
1996) and were approved by the Institutional Ani-
mal Care and Use Committee at our institution. A
partial ischemic rabbit hind limb model was devel-
oped to investigate the angiogenic potential of sus-
tained release of VEGF and other agents on ischemic
muscle tissue. A schematic of this model is shown in
Fig. 1. The left leg of adult male New Zealand White
rabbits (4 kg average weight) was made ischemic
surgically, while each right leg was left intact and
served as a nonischemic control. Rabbits were ran-
domly assigned to one of three treatment groups 
(n = 10 each): VEGF-treated limbs received 0.22
µg/day for 28 days (25 µg VEGF total); NTG-treat-
ed limbs received 17.8 µg/day for 28 days (2 mg
NTG total); and saline-treated limbs were perfused
with heparinized saline alone for 28 days. No sham
surgical control animals or nontreated controls ani-
mals were included in this study.
After a 7-day minimum acclimatization period,
each rabbit was anesthetized by intramuscular injec-
tion with a mixture of ketamine (50 mg/kg),
xylazine (2 mg/kg), and acepromazine (1 mg/kg).
Once a surgical plane of anesthesia was achieved, the
lower extremities were initially examined for signs of
infection, deformity, amount of hair growth, and the
presence of pulsatile blood flow in both hind feet.
Any nonconforming animals were excluded from the
study. The hair along the medial aspect of the left
thigh was shaved from the knee to the umbilicus,
exposing the skin of the left groin area. Standard ster-
ile surgical techniques were used throughout the
procedure. A longitudinal incision was made through
the skin and soft tissues overlying the femoral vessels,
extending superiorly to 1 cm above the inguinal lig-
ament and inferiorly to the mid thigh area. The
femoral artery was isolated from its origin just above
the inguinal ligament to its bifurcation at the origin
of the popliteal and saphenous arteries. All visible
arterial branches including the inferior epigastric,
deep femoral, lateral circumflex and superficial
femoral arteries were ligated at their attachments to
the femoral artery. A 3-0 silk tie was placed around
the femoral artery and slid proximally to the inguinal
ligament to control proximal blood flow. An arteri-
otomy of 1 mm was then made in the vessel 1 mm
below the inguinal ligament. With the aid of a vessel
guide, the tip of the pump catheter was placed into
the vessel and positioned such that the catheter tip
ended at the bifurcation of the nutrient internal iliac
artery. The catheter was then secured to the artery
with 3-0 silk. This functionally ligated the proximal
femoral artery, preventing flow distal to the insertion
site. The catheter tubing was flushed with 0.5 ml of
Fig. 1. Diagram of partial ischemia and VEGF delivery
produced in left hind limb of each rabbit. Right hind limb
served as a nonischemic control. Ligated vessels are indi-
cated. Left internal iliac artery served as a nutrient vessel
for VEGF delivery to adjacent ischemic tissue.
the complexity of vascular branching; and the vascu-
lar density index measured the total extent of vascu-
larization. In brief, fractal dimension is a unitless
parameter that ranges between 1.0 and 2.0. A value
of 1.0 describes a vessel with no branching; a value
of 2.0 describes a pattern of branching so complex
that the plane of analysis is completely filled. The
relationship between the values is not linear. There-
fore, subtle differences between respective fractal
dimensions may in fact represent major functional
differences.
Histology. Immediately after angiography, a 1
· 1 cm section of the gastrocnemius muscle was
removed from both ischemic and nonischemic hind
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heparinized saline and reattached to the pump. The
pump was then secured to the soft tissue of the left
flank with 4-0 vicryl suture. The overlying soft tissue
was reapproximated and the skin was closed with 4-0
vicryl suture. The limb was reevaluated for pedal per-
fusion and the rabbit allowed to recover in its cage.
Buprenorphine (0.04 mg/kg) was administered
intramuscularly as needed for pain.
Capillary refill and functional changes. After
pump implantation, each animal was observed daily
for general health. Vascular perfusion status of the
ischemic limbs was evaluated at postoperative weeks
1, 2, and 6, respectively. Capillary refill was mea-
sured as the time in seconds for the nail bed to
reperfuse with blood after 10 seconds of firm pres-
sure applied by hand to the foot and nail bed.
Although this method of determination of capillary
refill is a somewhat crude measure of perfusion,
more sophisticated methods of evaluation of blood
flow such as transcutaneous PO2 or laser Doppler
evaluations were not available. General appearance
of each ischemic limb was noted throughout the
study. Observations included skin and nail bed color,
incisional healing, presence of ulcerations, and pres-
ence of new hair growth. The functional use of each
ischemic limb was also observed throughout the
study, based on the overall mobility of each animal
and its ability to flex, move, and bear weight on the
limb. Although the investigator was blinded to the
treatment groups for these analyses, as the experi-
ment progressed the trophic changes became very
apparent in the ischemic saline-treated limbs.
Angiography. Angiographic evaluation of is-
chemic hind limbs was performed on postoperative
day 40. Because of limitations in equipment avail-
ability, angiography could only be performed at this
one time period. For angiography, each rabbit was
anesthetized, the abdominal aorta exposed, and an
18-gauge Angiocath was placed distally. With timed,
manual delivery of intravenous contrast material, a
digital fluoroscope recorded and stored an angio-
graphic image of the ischemic hind limb. A video
image of each arteriogram was digitized by capturing
it with a DT2871 frame grabber board and DT2879
video encoder (Data Translation, Marlboro, Mass.).
Vascular growth and collateral development of each
digital image were evaluated with Angiogen©, a frac-
tal analysis program previously validated by angio-
genesis studies of chorioallantoic membranes.21 All
visible vascular branches contained in a selected field
of the digitized image were traced with the comput-
er mouse. The program determined two parameters
of vascularity: the fractal dimension index measured
Fig. 2. A, Representative angiogram of VEGF-treated
ischemic (left) rabbit hind limb at postoperation day 40.
B, Representative angiogram of saline-treated ischemic
(left) rabbit hind limb at postoperation day 40. All
angiograms were digitized and evaluated with fractal
analysis software program to quantify complexity of vascu-
lar branching and overall vascular density.
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limbs, and stored in formalin. Muscle cross-sections
were cut, fixed, stained with hematoxylin and eosin,
and evaluated for capillary counts, fascicle density,
and morphology at · 400 under a light microscope.
Slides were interpreted by three blinded observers
counting multiple fields from each section.
Statistical analysis. Results are expressed as
mean value ± SEM for all data. Statistical compar-
isons between measured parameters in ischemic ver-
sus nonischemic limbs within treatment groups as
well as between groups were made by one-way
analysis of variance (ANOVA) with the Student-
Newman-Keuls multiple comparison method. The
Kruskal-Wallis one-way ANOVA on ranks procedure
was used to quantify data with unequal variance.
Differences between groups were considered to be
significant if p < 0.05.
RESULTS
Capillary refill. Table I summarizes the capil-
lary refill data for each treatment group. VEGF-
treated ischemic limbs achieved significantly better
Fig. 3. A, Representative transverse section of VEGF-treated ischemic (left) rabbit gastrocne-
mius muscle at postoperation day 40 (hematoxylin-eosin staining, original magnification
· 400). Note uniform muscle fascicle size and shape, with numerous capillary nuclei. 
B, Transverse section of saline-treated ischemic (left) rabbit gastrocnemius muscle at postop-
eration day 40 (hematoxylin-eosin staining, original magnification · 400). Saline-treated tissue
had irregular, nonuniform fascicles, with fewer capillary nuclei.
A
B
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capillary refill than either NTG-treated or saline-
treated limbs as early as 2 weeks after surgery (p <
0.001). Capillary refill times approached normal for
VEGF-treated ischemic limbs by postoperative
week 6 (p < 0.001). NTG-treated ischemic limbs
were not significantly improved compared with
saline-treated limbs.
Functional changes. Two weeks after surgery,
8 of 10 VEGF-treated ischemic limbs appeared
greatly improved in function and appearance, where-
as 2 limbs showed only moderate improvement.
This was determined by observations of new hair
growth, pink skin and nail beds, and well-healed
incisions with no ulcerations. By postoperative week
6, VEGF-treated ischemic limbs essentially matched
their nonischemic counterparts in appearance and
function. The animals were able to use the formerly
ischemic limbs to bear weight with full range of
motion and to ambulate with no obvious signs of
discomfort. The appearance and function of saline-
treated ischemic limbs contrasted sharply. They
remained cold, with dark skin and nail beds, negligi-
ble hair growth, and often revealed ulcerations and
other signs of skin necrosis. These limbs generally
remained stiff and nonfunctional throughout the
study. NTG-treated ischemic limbs showed little
improvement in function or physical appearance
compared with the saline-treated group.
Angiography. Figs. 2A and 3B show represen-
tative arteriograms of VEGF-treated and saline-
treated ischemic limbs, respectively. The extent of
vascular branching (measured by the fractal dimen-
sion index) and vascular density were both signifi-
cantly enhanced in VEGF-treated ischemic limbs
compared with both saline-treated and NTG-treated
ischemic limbs (p < 0.001). The results of the
Angiogen© analysis are summarized in Table II.
Histological analysis. Table III summarizes
the comparison of total capillaries per high power
field (HPF), as well as the number of capillaries per
mm2 in both ischemic and contralateral nonischemic
muscle tissue of each treatment group. The number
of capillaries in VEGF-treated ischemic muscle tissue
was significantly greater than the number of capillar-
ies in both ischemic and nonischemic muscle tissue
of saline-treated rabbits (p < 0.05). Despite the fact
that the mean capillary count of ischemic VEGF-
treated tissue was twice that of contralateral nonis-
chemic tissue, this difference was not statistically sig-
nificant as a result of high variability in the ischemic
VEGF group. This was also the case when compar-
ing ischemic VEGF-treated tissue to both ischemic
and nonischemic tissue of NTG-treated animals.
Ischemic NTG-treated limbs also had significant-
ly greater capillary counts compared with ischemic
saline-treated limbs (p < 0.05). However, capillary
counts did not differ significantly between ischemic
and contralateral nonischemic limbs of NTG-treated
rabbits.
Representative photomicrographs of ischemic
VEGF-treated and ischemic saline-treated tissue
are shown in Figs. 3A and 3B, respectively. Muscle
fascicles in ischemic saline-treated tissue were gen-
erally nonuniform in shape and size, with consider-
ably more space between fascicles and evidence of
cell damage. In contrast, ischemic VEGF-treated
fascicles were more uniform in size and shape, and
more tightly packed with little empty space
between fascicles.
To account for variability in number and size of
the muscle fascicles represented in different fields,
the number of capillaries per fascicle was also deter-
mined and summarized in Table III. When the total
number of capillaries per HPF is normalized to fas-
cicle number, NTG-treated ischemic tissue does not
differ significantly compared with other groups.
DISCUSSION
Recent studies have documented the therapeutic
angiogenic potential of VEGF. Increased blood
pressure in ischemic limbs, increased capillary
growth, vascular perfusion, and other physiologic
improvements have been reported after VEGF
administration.12,16 In these studies, delivery of
VEGF was achieved either by single bolus, intraarte-
rial injection, or alternatively through several intra-
muscular injections. Dosages of VEGF in all previ-
ous ischemia studies have been in the milligram
range. Our study attempted to discover whether a
sustained dose of VEGF, locally delivered at concen-
trations approximately 20- to 120-fold less than pre-
vious systemic doses, could promote neovasculariza-
tion and provide similar benefits to ischemic tissue.
We found that delivery of 25 µg of VEGF deliv-
ered through nutrient vessel to adjacent ischemic tis-
sue over a 28-day period greatly improved limb vas-
cularity, perfusion, function, and appearance com-
Table I. Capillary refill in ischemic hind limbs 
Capillary refill (sec) VEGF Nitroglycerin Saline
Postoperation week 1 14.29±0.71 16.25±1.25 15.71±0.71
Postoperation week 2 5.29±0.89* 14.17±0.83 16.25±0.82
Postoperation week 6 2.50±0.22* 14.00±1.00 15.63±0.63
*VEGF versus nitroglycerin and saline, p < 0.001.
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pared with NTG- or saline-treated ischemic limbs.
VEGF-treated ischemic limbs exhibited significantly
enhanced vascular density and complexity of vascu-
lar branching, higher numbers of capillaries, and
greatly improved capillary refill times. Most impres-
sive was their near-normal function and appearance,
based on observing improved range of motion,
weight-bearing capability, new hair growth, and
healthy skin color of VEGF-treated limbs compared
with ischemic controls. We did not observe any ede-
matous changes in the limbs associated with VEGF
treatment, which is an important issue because, in
addition to enhancing angiogenesis, VEGF is known
to be a stimulus for hyperpermeability. Collectively,
these results suggest that controlled, local delivery of
small quantities of VEGF has therapeutic value.
There are several potential advantages to sus-
tained release of microgram quantities of VEGF to
promote neovascularization. Clinical use of VEGF as
a therapeutic agent to treat peripheral vascular dis-
ease may ultimately require focal delivery, to avoid
any possible adverse systemic effects due to its
strong angiogenic potential. Uncontrolled systemic
delivery of inappropriate quantities of VEGF could
lead to tumorigenesis, hemangioma formation, mac-
ular degeneration, or other heretofore undiscovered
pathologic states.5,9,22 To prevent this, controlled
drug delivery is typically achieved by incorporation
of a pharmaceutical agent such as VEGF into
biodegradable polymers, microspheres or liposomes.
However, processing techniques can denature sensi-
tive proteins, often making encapsulation difficult.
Another limitation of biodegradable controlled
release polymers is their tendency to provide an ini-
tial aburst effect, causing a large portion of the total
drug available to be released within the first days.
Implantable osmotic pumps offer an alternative sim-
ple delivery method, providing a constant release of
soluble agents in a steady-state fashion. This tech-
nique has been used in a pig model of chronic
myocardial ischemia to administer 2 mg VEGF
extraluminally, resulting in significantly increased
coronary blood flow.11 Of course, local delivery
does not rule out the potential for systemic effects,
an issue that needs to be clarified in further studies.
A controlled release of VEGF may also be a very
realistic description of its actual metabolic fate in
vivo. Although the detailed mechanisms of VEGF
metabolism and regulation remain unclear, it has
been hypothesized that VEGF may bind to proteo-
glycans in the extracellular matrix and be slowly
released into the cellular environment.7 Similar
mechanisms have been shown to occur with other
growth factors.23 Another possibility is that after
VEGF binds to a receptor, a cascade of growth pro-
moters or still undefined intracellular mechanisms are
activated, resulting in endothelial cell growth and
neovascularization. It may therefore be advantageous
to constantly deliver microgram quantities of VEGF
over an extended period to ensure its bioavailability.
It should be noted, however, that the required VEGF
treatment period necessary to achieve satisfactory
anatomic and functional results is not known.
The controlled dosing regimen was tested in a
newly developed model of partial ischemia. This par-
tial ischemia model may accurately reflect the com-
Table II. Evaluation of neovascularization in ischemic hind limbs
Angiogen parameter VEGF Nitroglycerin Saline
Vascular density index 0.039±0.002* 0.025±0.002 0.023±0.002
Fractal dimension index (vascular branching) 1.829±0.058* 1.568±0.043 1.474±0.048
*Versus nitroglycerin-treated and saline-treated, p < 0.001.
Table III. Histologic evaluation of hind limb muscle
VEGF Nitroglycerin Saline
Ischemic Nonischemic Ischemic Nonischemic Ischemic Nonischemic
Total capillaries 97.2±16.10* 47.3±7.20 51.3±4.12† 46.7±3.77 20.3±2.18 23.1±1.94
Capillaries per mm2 773.4±128.0* 376.3±57.3 407.9±32.8† 371.7±30.0 161.8±17.3 184.1±15.5
Capillaries per fascicle 2.09±0.21* 1.22±0.20 0.93±0.05 0.90±0.06 0.34±0.11 0.79±0.24
*Versus normal and ischemic saline-treated limbs, p < 0.05.
† versus ischemic saline-treated limbs, p < 0.05.
pensatory events that occur in patients who live with
a viable, but ischemic limb. The partial ischemia is
proposed to mimic clinical rest pain situations,
where limb musculature is threatened but total
ischemia is avoided. Models that develop near total
perfusion deficits may be less applicable for this type
of study, because chronic, worsening limb ischemia
typically requires urgent surgical intervention to
ensure survival of the patient. Therefore in our
model the internal iliac artery served as a nutrient
vessel, supplying flow to the ischemic limb, with the
delivery catheter positioned at the origin of the
nutrient artery to provide optimal delivery of VEGF
to ischemic tissue.
Increased vascular perfusion and consequent
reduction of ischemia may also occur directly as a
result of vasodilation. Beneficial vasodilatory effects
could occur alone or in combination with neovascu-
larization. We compared VEGF with NTG because
NTG is a stable metabolic precursor of the potent
vasodilator, nitric oxide (NO). NTG is enzymatical-
ly reduced in vivo to produce NO.24 The 2 mg
quantity of NTG delivered through a pump was
based on an equivalent effective clinical dose of 5 to
10 µg/minute for treating angina in a 70 kg person
in our institution. Our data demonstrate, however,
only marginal enhancement in neovascularization
and limb function consequent to NTG-treatment.
Possible limitations of NTG therapy may include
rapid degradation and/or an inability of the
ischemic tissues to metabolize NTG and release suf-
ficient quantities of NO to provide a vasodilatory
effect. In addition, opposing interactions between
regulation of NO and VEGF in hypoxic tissue may
explain the poor perfusional outcomes from NTG
treatment. Initiation of hypoxia results in an imme-
diate increase in VEGF mRNA expression, as well as
that of VEGF receptors flt1 and flk1.19,25,26 Con-
versely, hypoxia decreases NO synthase (NOS)
expression from endothelial cells.18 Several recent
studies have shown that exogenous NO donors such
as sodium nitroprusside decrease expression of
VEGF as well as flt1 and flk1, whereas inhibitors of
NO synthesis stimulate VEGF and receptor expres-
sion.19 VEGF expression or infusion has also been
shown to up regulate NOS in rabbit and human
endothelial cells.18 Therefore VEGF administration
alone may be sufficient to provide the appropriate
levels of NO production and subsequent vasodila-
tion in ischemic tissue, in contrast to the lack of
effect from exogenous NTG administration. It
should be noted, however, that higher doses of
NTG may have produced a more salutary effect.
The capillary count data suggest that a systemic
effect may have resulted from local delivery of
VEGF or NTG to the ischemic limb. In both cases,
contralateral nonischemic limbs had greater num-
bers of capillaries than those of the saline-treated
animals, although the differences between groups
were not significant. This might have been a result
of the hypoxic status of the iliofemoral region of the
ischemic leg that induced VEGF and receptor
expression in nearby nonischemic tissue. However,
preliminary results from immunohistochemical eval-
uation of tissue samples to evaluate pericyte density
(and hence actively growing capillaries) with an anti-
body to the intermediate filament protein desmin27
suggest that VEGF-treated tissue had greater peri-
cyte density than contralateral nonischemic controls,
as well as saline-treated and NTG-treated ischemic
tissue. This issue remains to be clarified.
Finally, it should be noted that the two VEGF-
treated ischemic limbs with the moderate functional
improvement also had the lowest mean capillary
counts of the treatment group. The failure of the
osmotic pumps in these cases cannot be ruled out,
because no effort was made to assay any VEGF that
may have remained in the pumps at the study end-
point.
It is clear that patients with profound ischemia
due usually to multiple levels of arterial occlusion
may not respond to VEGF as nicely as did the rab-
bits in this study. Nevertheless, as therapeutic tech-
niques become less invasive and more sophisticated,
the field of therapeutic angiogenesis will become
continually more attractive to researchers and clini-
cians. It is clear that further studies are required to
elucidate the numerous effects of VEGF administra-
tion, and to optimize dosing, delivery, and duration
schemes to assure safe clinical use.
CONCLUSIONS
Controlled release of microgram quantities of
VEGF into a nutrient artery significantly enhanced
neovascularization and vascular perfusion in ischemic
limbs compared with controls in this rabbit model of
partial ischemia. VEGF-treated ischemic limbs also
demonstrated near-normal function and appearance,
whereas NTG- and saline-treated ischemic controls
remained noticeably impaired. Future studies should
focus on the cellular events that occur with the initia-
tion of VEGF treatment in hypoxic tissues and the
functional quantities of growth factors necessary to
produce angiogenesis. In a clinical setting, these
results may offer an opportunity to restore perfusion
in patients with debilitating peripheral vascular disease.
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smoke and some of whom have diabetes, hypertension,
and hyperlipidemia that may be difficult to control? Have
you extended these studies to look at diabetic animals,
rabbits put in smoke chambers, hypercholesterolemic ani-
mals?
This is a nice paper, and I appreciate the opportunity
for discussion.
Dr. Steven P. Hopkins. I will respond first to your
question on why we chose the dose we chose. Previous
investigators had used doses in the 1 mg to 5 mg range 
to document angiogenesis, working with a hindlimb
ischemia model. They recommended that we try a lower
dose. It was a wide-open dose, and we chose 25 m g over
28 days, which is about 10-8g/kg dose. Physiologically,
the estimated dose is about 10-9g/kg for a mildly ischemic
event—not a total ischemic event—just upregulation of
vascular endothelial growth factor receptor. So, we are
very close, just above the normal physiologic dose. At the
beginning, we were afraid that may have been too low.
Heparin was used in the pump. Part of the procedure
is to use a pump such that the tubing does not clot. There
were 100 units in every pump in all groups.
The entire study was blinded. There were questions of
bias in the trophic changes, and significance was not
applied to those changes because of nonblinded-observer
bias.
To answer your question about patients, Dr. Eisner
has given a viral vector–induced gene that does up regu-
late vascular endothelial growth factor to one patient, and
there was a prolongation of flow to her right foot. How-
ever, she subsequently required amputation, so we do not
know yet. We are still in the preliminary stages.
Dr. Robert W. Thompson (St. Louis, Mo.). First of
all, I would like to congratulate the authors on their paper.
I think that work in the basic science field is particularly
interesting to this group because we all have been in the
situation where we review the arteriogram and the MRA,
and we go talk to a patient, and we say we cannot do a dis-
tal bypass graft because the outflow vessel is not adequate.
Of course the next question is what else can be done, and
at that point we are talking to patients about amputation.
So, from that standpoint this work is exciting.
In the perspective of other work that has been done in
the area, this work is also interesting because it uses a
chronic infusion of a low dose rather than higher doses as
a bolus as previous studies have used. Thus I think it also
is exciting from that standpoint. 
I have three questions for the authors. First, in terms
of your experimental design, how did you choose the dose
that you used for this study? We know that if you induce
ischemia that you will get release of vascular endothelial
growth factor. Is this a physiologic dose, and have you
simply prolonged the release of that dose?
Second, in terms of methods, heparin will release
growth factors from tissue by releasing them from matrix.
Were all three groups controlled in terms of the amount of
heparin that they received?
Lastly, some of the parameters that you measured were
subjective. Was this a blinded study?
Other questions deal with the direction in which you
might be going with this. Have you looked at other
growth factors, such as fibroblast growth factor? Of
course, a question that is of clinical importance is would
this work in our patients, some of whom continue to
DISCUSSION
